Fresenius buys rights to RenalTech's BetaSorb:
This article was originally published in Clinica
Executive Summary
Fresenius Medical Care has bought exclusive North American distribution rights to RenalTech's BetaSorb device as an accessory to hemodialysis. Fresenius and RenalTech expect to announce a similar agreement for international markets this week. Fresenius will carry out multicentre outcome studies of the device, which is based on RenalTech's adsorbent polymer technology for blood detoxification, once US and EU regulatory approval is granted. Fresenius will also make a series of equity investments in the New York-based company in the form of upfront and milestone payments.